Jove
Visualize
联系我们
JoVE
x logofacebook logolinkedin logoyoutube logo
关于 JoVE
概览领导团队博客JoVE 帮助中心
作者
出版流程编辑委员会范围与政策同行评审常见问题投稿
图书馆员
用户评价订阅访问资源图书馆顾问委员会常见问题
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experiments存档
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教师资源中心教师网站
使用条款与条件
隐私政策
政策

相关概念视频

Blood Studies for Cardiovascular System I: Cardiac Biomarkers01:20

Blood Studies for Cardiovascular System I: Cardiac Biomarkers

749
Cardiac biomarkers are enzymes, proteins, and hormones released into the blood when cardiac cells are injured. They are powerful tools for triaging.
The essential diagnostic tools for detecting myocardial necrosis and monitoring individuals suspected of having acute coronary syndrome (ACS) include:
Troponins
Troponins, particularly cardiac troponins I and T, are the most precise and sensitive markers of myocardial injury. They are detectable within 4-6 hours of myocardial injury and remain...
749
Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers01:19

Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers

516
Cardiac biomarkers are critical in diagnosing, prognosing, and managing cardiovascular diseases. Routine measurement of specific biomarkers such as B-type natriuretic peptide (BNP), C-reactive protein (CRP), and homocysteine (Hcy) is common practice in clinical settings to evaluate heart function and predict cardiovascular events.
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
516

您也可能阅读

相关文章

通过共同作者、期刊和引用图与本文相关的文章。

排序
Same author

Cortical gray-white matter contrast alterations precede amyloid-β positivity and macrostructural changes in older adults without dementia.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same author

Trajectories of brain structure and function in young adult carriers of genetic frontotemporal dementia variants.

medRxiv : the preprint server for health sciences·2026
Same author

Fibroblasts carrying intermediate C9orf72 hexanucleotide repeat expansions from iNPH patients show changes in energy metabolism but no cell pathologies.

Biochimica et biophysica acta. Molecular cell research·2026
Same author

Orbitofrontal atrophy on MRI appears to be an indicator of C9orf72 repeat expansion status in FTD.

Journal of neuroradiology = Journal de neuroradiologie·2026
Same author

Biobank-based genetic characterization of neurodegenerative diseases and idiopathic normal pressure hydrocephalus: insights and lessons learned from FinnGen.

Molecular psychiatry·2026
Same author

Appropriate use recommendations of the Spanish Society of Neurology's Behavioural Neurology and Dementia Study Group on anti-amyloid antibodies in the treatment of Alzheimer disease.

Neurologia·2026
Same journal

Unveiling the procoagulant state in Alzheimer's disease: A novel PET imaging strategy.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same journal

Estimated labor market outcomes of people progressing from preclinical to early-stage Alzheimer's disease in the United States.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same journal

Amyloid exacerbates tau and alpha-synuclein pathologies, behavioral impairments, and neuroinflammation in a mixed dementia model.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same journal

Multimorbidity burden and patterns associated with DeepBrainNet-derived brain-age gap in dementia-free older adults: A community-based study.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same journal

Reply to "Shifting the emphasis of brain health literacy from individuals to systems to reduce inequalities".

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same journal

Shifting the emphasis of brain health literacy from individuals to systems to reduce inequalities.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
查看所有相关文章

相关实验视频

Updated: Jan 7, 2026

Dried Blood Spot Collection of Health Biomarkers to Maximize Participation in Population Studies
07:20

Dried Blood Spot Collection of Health Biomarkers to Maximize Participation in Population Studies

Published on: January 28, 2014

37.1K

生物标志物 生物标志物

Pablo Martinez-Lage1, Eino Solje2,3, Julian G Martins4

  • 1Center for Research and Memory Clinic, CITA-Alzheimer Foundation, San Sebastián, Gipuzkoa, Spain.

Alzheimer's & dementia : the journal of the Alzheimer's Association
|December 24, 2025
PubMed
概括
此摘要是机器生成的。

脑脊液中tau与粉样β 42 (pTau/Aβ42) 的比率在诊断阿尔茨海默病 (AD) 时比其他比率更准确. 这一发现表明pTau/Aβ42可能是确认AD诊断的首选生物标志物.

更多相关视频

Selecting Multiple Biomarker Subsets with Similarly Effective Binary Classification Performances
07:35

Selecting Multiple Biomarker Subsets with Similarly Effective Binary Classification Performances

Published on: October 11, 2018

7.9K
Ecotoxicological Methodologies to Evaluate Biomarkers at Different Scales in Neotropical Anurans
08:14

Ecotoxicological Methodologies to Evaluate Biomarkers at Different Scales in Neotropical Anurans

Published on: April 28, 2023

702

相关实验视频

Last Updated: Jan 7, 2026

Dried Blood Spot Collection of Health Biomarkers to Maximize Participation in Population Studies
07:20

Dried Blood Spot Collection of Health Biomarkers to Maximize Participation in Population Studies

Published on: January 28, 2014

37.1K
Selecting Multiple Biomarker Subsets with Similarly Effective Binary Classification Performances
07:35

Selecting Multiple Biomarker Subsets with Similarly Effective Binary Classification Performances

Published on: October 11, 2018

7.9K
Ecotoxicological Methodologies to Evaluate Biomarkers at Different Scales in Neotropical Anurans
08:14

Ecotoxicological Methodologies to Evaluate Biomarkers at Different Scales in Neotropical Anurans

Published on: April 28, 2023

702

科学领域:

  • 神经学 神经学
  • 生物标志物发现发现
  • 诊断的准确性 诊断的准确性

背景情况:

  • 粉样PET是阿尔茨海默病 (AD) 诊断的黄金标准,但成本昂贵,可用性有限.
  • 大脑脊髓液 (CSF) 生物标志物比率提供了一个具有成本效益的替代方案,与粉样蛋白PET具有很高的一致性.
  • 不同的CSF生物标志物比率与粉样蛋白PET的比较诊断准确性仍然不清楚.

研究的目的:

  • 进行诊断测试准确性 (DTA) 的元分析,比较三种CSF生物标志物比率 (Aβ42/Aβ40,pTau/Aβ42和tTau/Aβ42) 与粉样蛋白PET的一致性.
  • 为了确定pTau/Aβ42或tTau/Aβ42比率是否与广泛研究的Aβ42/Aβ40比率相比,提供了更好的一致性.

主要方法:

  • 通过Medline和Embase的系统文献搜索 (2008年1月 - 2024年10月) 寻找报告CSF生物标志物比率和粉样蛋白PET一致性的研究.
  • 使用双变量模型进行诊断测试准确度元分析,包括总结接收器操作特征 (SROC) 曲线,SROC曲线下的面积 (AUC) 值和元回归.
  • 使用Reitsma双变模型与R包 mada v0.5.11.11进行的统计分析.

主要成果:

  • 包括31项涉及6,238名患者的研究;大多数是前性观察性研究.
  • 所有三种CSF比率都显示出与粉样蛋白PET相比,对AD诊断的高灵敏度和特异性.
  • 与Aβ42/Aβ40 (AUC 0.944) 和tTau/Aβ42 (AUC 0.948) 相比,pTau/Aβ42比率显示出显著更高的SROC AUC (0.960) 和较低的假阳性率.

结论:

  • 所有评估的CSF生物标志物比率都与用于AD诊断的粉样蛋白PET高度一致.
  • 与Aβ42/Aβ40和tTau/Aβ42.2相比,pTau/Aβ42比率显示出与粉样蛋白PET阳性度的优异一致性.
  • 建议pTau/Aβ42作为确认阿尔茨海默病诊断的首选CSF生物标志物比率.